Precision Medicine : Dell and TGen extend partnership

Dell Inc. has extended its partnership with Translational Genomics Research Institute (TGen) to assist reasearchers and physicians expand the impact and reach of precision medicine efforts for pediatric cancer.

The partnership will be focused on helping clinical researchers and physicians expand globally and ensure that ensure the outreach and impact of the FDA approved precision medicine for pediatric cancer increases.

The renewed commitment from Dell and TGen will give an impetus of additioinal $3 million grant from Dell to TGen and support the Neurobllastoma and Medulloblastoma Translational Research Consortium’s (NMTRC) expanded pediatric cancer trials in EMEA, beginning with sites in France and Lebanon.

This second grant from Dell will enable TGen to support sequencing for other medical conditions affecting children including rare childhood diseases.

4 comments

Leave a Reply to Lukas Cancel reply

Your email address will not be published. Required fields are marked *